Viewing nowCombinationIdaldipine 40/5 mg (Azilsartan Medoxomil Potassium, Amlodipine Besylate)
Potassium Azilsartan Medoxomil 42.68mg · Amlodipine Besylate 6.945mg
Tablet · Prescription medication · Combination
(Co., Ltd. ) Celltrion

MFDS item code 202502800 · Approved 2025.10.29 · Insurance code 623800390
Treatment of essential hypertension not controlled with monotherapy
Azilsartan Medoxomil and Amlodipine are used together when blood pressure is not sufficiently controlled by monotherapy in patients with essential hypertension, effectively lowering blood pressure. These medications help to stabilize blood pressure by dilating blood vessels, reducing the risk of cardiovascular complications. Therefore, the combination therapy of Azilsartan Medoxomil and Amlodipine is an effective treatment option for hypertensive patients who find it challenging to control their blood pressure.
Adults Take 1 tablet once daily with water, with or without food. It is recommended to take the tablet at the same time each day (e.g., in the morning), if possible. 40/5 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 40 mg or amlodipine 5 mg monotherapy. 40/10 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 40 mg or amlodipine 10 mg monotherapy, or with this drug 40/5 mg. 80/5 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 80 mg monotherapy. 80/10 mg: For patients whose blood pressure is not adequately controlled with azilsartan medoxomil 80 mg or this drug 80/5 mg. Patients taking each of the individual drugs concomitantly may switch to this drug (a combination product containing the same amount of each active ingredient) for convenience. Elderly patients Dosage adjustment is generally not necessary; however, for patients 75 years of age or older, an initial dose of azilsartan medoxomil 20 mg should be considered, so starting treatment with this drug is not recommended. Patients with renal impairment Dosage adjustment is not necessary in patients with mild or moderate renal impairment. Patients with hepatic impairment For patients with mild to moderate hepatic impairment, an initial dose of azilsartan medoxomil 20 mg should be considered, so starting treatment with this drug is not recommended. Patients with intravascular volume depletion For patients who are salt-depleted or may have reduced effective circulating volume (e.g., those with vomiting or diarrhea, or those receiving high doses of diuretics), an initial dose of azilsartan medoxomil 20mg should be considered, so starting treatment with this drug is not recommended.
The safety and efficacy of this drug have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Individuals with hypersensitivity to this drug or its components, as well as pregnant or nursing women, should not take this medication. Diabetic patients or those with moderate to severe renal impairment should not use this medication in conjunction with certain drugs. Patients with severe liver dysfunction, aortic stenosis, or cardiogenic shock should also avoid using this medication. Patients with heart failure or renal function reliant on the renin-angiotensin-aldosterone system should use this drug with caution, and blood pressure and renal function should be closely monitored. In patients with decreased blood volume, hypotension may occur after taking this medication, so volume correction should be performed prior to administration or it should be started under medical supervision. Patients at risk of hyperkalemia should regularly check their serum potassium levels and exercise particular caution when taking potassium-sparing diuretics or potassium supplements concurrently with this medication. This drug may cause side effects such as dizziness, headache, hypotension, and peripheral edema, and patients should consult healthcare professionals if symptoms are severe. In patients with impaired liver function, the metabolism of this drug may slow down, requiring dose adjustments and monitoring. There may be instances of excessively low blood pressure or deteriorating renal function, so especially in older patients or those with heart failure, it’s recommended to start with a low dose and gradually increase it. In cases of overdose, hypotension and dizziness may occur, and if needed, appropriate treatment and monitoring should be administered. This medication has not been established for safety and efficacy in children and adolescents, so its use is not recommended. During administration, drowsiness or dizziness may occur; therefore, caution should be exercised when driving or operating hazardous machinery.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container as it may be sensitive to air and moisture. It is recommended to maintain a storage temperature between 1 degree and 30 degrees Celsius so that the efficacy of the drug can be preserved.
Pale red oval film-coated tablet
30 tablets/PTP[(15 tablets*2ea)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationPotassium Azilsartan Medoxomil 42.68mg · Amlodipine Besylate 6.945mg
Tablet · Prescription medication · Combination
(Co., Ltd. ) Celltrion
CombinationPotassium Azilsartan Medoxomil 85.36mg · Amlodipine Besylate 13.889mg
Tablet · Prescription medication · Combination
Celltrion, Inc.
CombinationPotassium Azilsartan Medoxomil 85.36mg · Amlodipine Besylate 6.945mg
Tablet · Prescription medication · Combination
Celltrion, Inc.
CombinationPotassium Azilsartan Medoxomil 42.68mg · Amlodipine Besylate 13.889mg
Tablet · Prescription medication · Combination
Celltrion, Inc.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.